Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135330 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 137
- Enrollment target
NCT00135330 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 137 participants.
The verdict
NCT00135330, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 137 participants
- Enrollment target
Study Summary
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
Interventions
- DRUG exenatide
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135330
The ClinicalTrials.gov registry entry for NCT00135330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exenatide is the first listed.
NCT00135330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135330 about?
NCT00135330 is a clinical study titled "An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus". This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
What is the current status of trial NCT00135330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 137 participants. The study started on 2005-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00135330?
The interventions under investigation include: exenatide (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00135330?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.